Log in

Relevant bibliographies by topics / Systemic thrombolysis / Journal articles

To see the other types of publications on this topic, follow the link: Systemic thrombolysis.

Journal articles on the topic 'Systemic thrombolysis'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Systemic thrombolysis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bajka, Balázs, Edvin Benedek, Alexandra Stănescu, Emese Rapolti, Monica Chițu, and István Kovács. "Treatment Difficulties in High Risk Pulmonary Embolism. A Case Report." Journal Of Cardiovascular Emergencies 2, no. 1 (2016): 37–42. http://dx.doi.org/10.1515/jce-2016-0007.

Full text

Abstract:

Abstract Pulmonary embolism (PE) remains a common and potentially life-threatening cardiovascular emergency. Systemic thrombolysis with intravenous infusion of a thrombolytic agent is generally recommended for treatment of high risk PE. However, this method has known limitations in the presence of high bleeding risk. Catheter-directed thrombolysis has the potential to achieve the same benefits as systemic thrombolysis, with a lower risk of haemorrhage. The case presented is of a 67-year-old male patient with a high risk of pulmonary embolism and contraindications for systemic thrombolysis, in

APA, Harvard, Vancouver, ISO, and other styles

2

Terrin, Alberto, Giulia Toldo, Mario Ermani, Federico Mainardi, and Ferdinando Maggioni. "When migraine mimics stroke: A systematic review." Cephalalgia 38, no. 14 (2018): 2068–78. http://dx.doi.org/10.1177/0333102418767999.

Full text

Abstract:

Background Migraine with aura may mimic an acute ischemic stroke, so that an improper administration of thrombolytic treatment can expose migrainous patients to severe adverse effects. Methods This systematic review quantifies the relevance of migraine with aura among stroke mimics, checking for thrombolysis’ safety in these patients. We reviewed the literature after 1995, distinguishing from studies dealing with stroke mimics treated with systemic thrombolysis and those who were not treated with systemic thrombolysis. Results Migraine with aura is responsible for 1.79% (CI 95% 0.82–3.79%) of

APA, Harvard, Vancouver, ISO, and other styles

3

Knoll, Thomas, Christian Weimar, Roman L. Haberl, et al. "Systemic Thrombolysis Data from the German Stroke Database." Stroke 32, suppl_1 (2001): 337. http://dx.doi.org/10.1161/str.32.suppl_1.337-b.

Full text

Abstract:

118 Objectives: To present data on systemic thrombolysis for acute ischemic stroke from a cooperative database of 23 german hospitals. Methods: All admitted stroke patients in the participating centers were prospectively recruited into a 599-item database including a telephone follow-up 3 months after stroke. Findings: From 01/1998 until 11/1999, 5279 patients with acute ischemic stroke were included in the database, 205 (3.9%) had systemic thrombolysis with 0.9mg/kg rt-PA (alteplase). Three hospitals did not perform thrombolysis (range of thrombolysis rate 0–11.3%). The median age of patients

APA, Harvard, Vancouver, ISO, and other styles

4

Cheema, Ali Akhtar, Robert H. Mallinson, and Nicola Trepte. "Advances in Deep Vein Thrombosis Management with Thrombolysis." Acute Medicine Journal 8, no. 2 (2009): 63–69. http://dx.doi.org/10.52964/amja.0234.

Full text

Abstract:

Lower extremity deep vein thrombosis (DVT) is a common disease associated with serious short term and long term complications. Its conventional treatment has been anticoagulation. Thrombolytic treatment has been used for DVT for over 40 years. More recently catheter directed thrombolysis has taken over systemic thrombolysis. This technique is useful to prevent post thrombotic syndrome (PTS) after DVT. In this review article we present a case of DVT thrombolysis in our hospital, look at the pathophysiology of PTS, the mechanism of thrombolysis and the current status of thrombolysis in DVT.

APA, Harvard, Vancouver, ISO, and other styles

5

Latfullin, I. A., A. V. Bondarev, A. A. Podolskaya, and E. I. Aglullina. "Thrombolytic therapy of the acute myocardial infarction by cabicinase." Kazan medical journal 79, no. 4 (1998): 251–54. http://dx.doi.org/10.17816/kazmj64386.

Full text

Abstract:

The necessity to perform the systemic thrombolysis to patients with acute myocardial infarction is emphasized. The most effective and save thrombolytic agent is cabicanase. The recommendations for practical physicians are worthy of notice. The control of blood coagulability velocity and hemorrhage lingering is obligatory in the performance of thrombolysis; if it is possible, thrombelastograms are to be studied. It is essential to know well the contradictions to thrombolysis.

APA, Harvard, Vancouver, ISO, and other styles

6

Domashenko, Maksim A., Marina Yu Maksimova, and Marine M. Tanashyan. "Intravenous thrombolysis in ischemic stroke: clinical predictors of efficacy and safety." Annals of Clinical and Experimental Neurology 13, no. 1 (2019): 5–14. https://doi.org/10.25692/acen.2019.1.1.

Full text

Abstract:

Introduction. Systemic thrombolysis with recombinant tissue plasminogen activator is the gold standard of reperfusion therapy, having the maximum level of evidence in European and North American guidelines for the treatment of patients with acute ischemic stroke (IS).Objective: to determine factors of individual efficacy and safety of systemic thrombolysis in patients with IS aiming to establish personalized approach to its optimization.Materials and methods. The study included 396 patients with IS, of whom 196 patients underwent systemic thrombolysis with recombinant tissue plasminogen activa

APA, Harvard, Vancouver, ISO, and other styles

7

Geraets, Douglas R., James D. Hoehns, Timothy G. Burke, and Maleah Grover‐McKay. "Thrombolytic‐Associated Cholesterol Emboli Syndrome: Case Report and Literature Review." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 15, no. 4 (1995): 441–50. http://dx.doi.org/10.1002/j.1875-9114.1995.tb04380.x.

Full text

Abstract:

Thrombolytics can cause cholesterol embolization syndrome (CES). This adverse effect has received less attention than other risks of thrombolytic therapy, such as systemic bleeding and hemorrhage, with only sporadic reports of CES in the literature. Risk factors have not been consistently identified and emphasized; therefore, occurrence of CES after thrombolysis remains difficult to predict, it results in substantial morbidity and mortality, and it lacks effective pharmacologic treatment. Heightened awareness of the disorder can aid in its correct identification and reporting.

APA, Harvard, Vancouver, ISO, and other styles

8

Barca-Hernando, María, and Luis Jara-Palomares. "When should we involve interventional radiology in the management of acute pulmonary embolism?" Breathe 19, no. 3 (2023): 230085. http://dx.doi.org/10.1183/20734735.0085-2023.

Full text

Abstract:

Pulmonary embolism (PE) is a common disease associated with high morbidity and mortality. Currently, guidelines recommend systemic thrombolysis in patients with haemodynamic instability (high-risk PE) or patients with intermediate–high-risk PE with haemodynamic deterioration. Nevertheless, more than half of high-risk PE patients do not receive systemic thrombolysis due to a perceived increased risk of bleeding. In these cases, percutaneous catheter-directed therapy (CDT) or surgical embolectomy should be considered. CDT has emerged and appears to be an effective alternative in treating PE, wit

APA, Harvard, Vancouver, ISO, and other styles

9

Saraswathi, T., T. Gopinathan, Balakumaran Balakumaran, and Yuvaraj Y. "Obstructive Shock Pulmonary Embolism: Catheter Directed Thrombolysis." Journal of Clinical Cases and Reports 6, S14 (2023): 254–56. http://dx.doi.org/10.46619/joccr.2023.6-s14.1079.

Full text

Abstract:

Venous thromboembolism is one of the most frequently encountered condition for which patients need intensive care admission often. Most of the time patients presents with shock and hemodynamic instability if it is massive pulmonary embolism. Incidence of Vte is comparable to western population in India, studies conducted by Ayyapan et all say it around 20/10,000 admission. Studies showed higher mortality of around 50% in high risk (massive) and mortality of around 14% in intermediate risk (sub-massive) PE which necessitating more aggressive approach in high-risk groups. Rapid administration of

APA, Harvard, Vancouver, ISO, and other styles

10

Chiasakul, Thita, and Kenneth A. Bauer. "Thrombolytic therapy in acute venous thromboembolism." Hematology 2020, no. 1 (2020): 612–18. http://dx.doi.org/10.1182/hematology.2020000148.

Full text

Abstract:

Abstract Although anticoagulation remains the mainstay of treatment of acute venous thromboembolism (VTE), the use of thrombolytic agents or thrombectomy is required to immediately restore blood flow to thrombosed vessels. Nevertheless, systemic thrombolysis has not clearly been shown to improve outcomes in patients with large clot burdens in the lung or legs as compared with anticoagulation alone; this is in part due to the occurrence of intracranial hemorrhage in a small percentage of patients to whom therapeutic doses of a thrombolytic drug are administered. Algorithms have been developed t

APA, Harvard, Vancouver, ISO, and other styles

11

Gu, Boram, Yu Huang, Emily Louise Manchester, et al. "Multiphysics Modelling and Simulation of Thrombolysis via Activated Platelet-Targeted Nanomedicine." Pharmaceutical Research 39, no. 1 (2022): 41–56. http://dx.doi.org/10.1007/s11095-021-03161-2.

Full text

Abstract:

Abstract Purpose This study establishes a multiphysics simulation platform for both conventional and targeted thrombolysis using tissue plasminogen activator (tPA). Based on our computational results, the effects of therapeutic parameters on the dynamics of thrombolysis and the risk of side effects are investigated. Methods The model extends our previously developed one-dimensional(1D) mathematical models for fibrinolysis by incorporating targeted thrombolysis. It consists of two parts: (i) a coupled mathematical model of systemic pharmacokinetics (PK) and pharmacodynamics (PD) and local PD in

APA, Harvard, Vancouver, ISO, and other styles

12

Macovei, Liviu, Razvan Mihai Presura, Robert Magopet, et al. "Local Thrombolysis in High-Risk Pulmonary Embolism—13 Years Single-Center Experience." Clinical and Applied Thrombosis/Hemostasis 26 (January 1, 2020): 107602962092976. http://dx.doi.org/10.1177/1076029620929764.

Full text

Abstract:

To evaluate the prognosis after local thrombolysis compared to systemic thrombolysis in high-risk pulmonary embolism. Observational study during 13 years which included 37 patients with high-risk pulmonary embolism treated with local thrombolysis and 36 patients with systemic thrombolysis (streptokinase, 250 000 UI/30 minutes followed by 100 000 UI/h). Cardiogenic shock has totally remitted in the group with local thrombolysis ( P = .002). The decrease in pressure gradient between right ventricle and right atrium was comparable in both groups in the acute period (the results being influenced b

APA, Harvard, Vancouver, ISO, and other styles

13

Benbahia, A., S. Bezza, L. Chemaou, et al. "Spontaneous Pulmonary Hemorrhage Following Thrombolytic Therapy for Acute Myocardial Infarction." SAS Journal of Medicine 8, no. 4 (2022): 345–50. http://dx.doi.org/10.36347/sasjm.2022.v08i04.025.

Full text

Abstract:

Systemic thrombolysis in the setting of acute myocardial infarction (AMI) remains an effective treatment. However, it exposes to a non-negligible bleeding risk Diffuse pulmonary hemorrhage is a of the rare complication of thrombolysis, it can cause a serious medical emergency potentially leading to fatal acute respiratory failure. We present four cases of diffuse pulmonary hemorrhage following administration of intravenous thrombolytic therapy (Tenecteplase), the Lack of recognition that the lungs too may be a site of spontaneous hemorrhage during thrombolytic therapy may lead to a considerabl

APA, Harvard, Vancouver, ISO, and other styles

14

Geuzebroek, Guillaume SC, Jan Wille, Jean-Paul de Vries, Wouter Schonewille, and Jan-Albert Vos. "Trapped cerebral thrombectomy device: A case report of a rare complication." Vascular 23, no. 2 (2014): 179–82. http://dx.doi.org/10.1177/1708538114535393.

Full text

Abstract:

Intravenous thrombolysis with recombinant tissue plasminogen activator is currently the standard therapy for acute ischaemic stroke when started within 4.5 h of symptom onset. Systemic thrombolytic therapy can, however, lead to potentially lethal bleeding complications and is contra-indicated in several circumstances. Intra-arterial thrombolysis and/or intra-arterial thrombectomy can overcome these drawbacks and even increase the rate of recanalization. While intravenous thrombolysis is a relatively non-complex treatment, intra-arterial therapy in acute ischaemic stroke patients requires a ded

APA, Harvard, Vancouver, ISO, and other styles

15

Yang, Yilin, Boram Gu, and Xiao Yun Xu. "In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke." Pharmaceutics 15, no. 3 (2023): 797. http://dx.doi.org/10.3390/pharmaceutics15030797.

Full text

Abstract:

Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase. This paper evaluates the efficacy and safety of urokinase, ateplase, tenecteplase, and reteplase for intravenous AIS therapy by computational simulations of the pharmacokinetics and pharmacodynamics combined with a local fibrinolysis model. The performances of the drugs are evaluated by comparing clot lysis time, plasminogen activator inhibitor (PAI) inhibition resistance, intracranial hemorrhage (ICH) risk

APA, Harvard, Vancouver, ISO, and other styles

16

Mostajeran, Kathy, Hillary Boswell, and Ziad Haidar. "Systemic Thrombolysis for Treatment of Postpartum Saddle Embolism Complicated by Postpartum Hemorrhage: A Case Report and Brief Literature Review." Case Reports in Obstetrics and Gynecology 2021 (June 29, 2021): 1–6. http://dx.doi.org/10.1155/2021/5553296.

Full text

Abstract:

Venous thromboembolic events (VTE), specifically pulmonary embolisms, account for a significant portion of maternal morbidity and mortality. Due to the procoagulant physiological changes that occur, pregnancy and the postpartum period are known risk factors for thromboembolic events. The risk is greatest during the first-week postpartum and remains elevated for up to six weeks as compared to the general population. Treatment guidelines regarding the use of thrombolytics for massive pulmonary embolism occurring in pregnancy and the postpartum are not well established. In nonpregnant populations

APA, Harvard, Vancouver, ISO, and other styles

17

Mulla, A., and K. de Wit. "P106: Systemic thrombolysis for suspected high-risk pulmonary embolism: a retrospective medical record review." CJEM 20, S1 (2018): S94. http://dx.doi.org/10.1017/cem.2018.304.

Full text

Abstract:

Introduction: Current treatment guidelines advocate for the aggressive management of both high-risk and subsets of moderate-risk pulmonary embolism (PE) with fibrinolytic therapy. However, there is limited evidence on the risks and benefits of fibrinolytic therapy in PE, with mortality improvement still to be proven. This study aimed to report the incidence of major bleeding and death after thrombolysis for PE. Methods: A health records review was performed on data from two hospitals between 2007 and 2017. Pharmacy identified all patients who had received either alteplase or tenecteplase. Trai

APA, Harvard, Vancouver, ISO, and other styles

18

Minina, Yuliya D., Vladimir A. Kalinin, and Anastasiya S. Tkachenko. "Modeling the outcomes of thrombolytic therapy in ischemic stroke." Science and Innovations in Medicine 7, no. 4 (2022): 239–44. http://dx.doi.org/10.35693/2500-1388-2022-7-4-239-244.

Full text

Abstract:

Aim to predict the effectiveness of systemic thrombolysis based on a comprehensive assessment of risk factors at the stage of decision making for thrombolytic therapy. Material and methods. The study included 110 ischemic stroke patients hospitalized between 2016 and 2021 who received the rt-PA systemic thrombolytic therapy. Depending on the outcome of the disease, all patients were ranked into two groups. Group I (favorable outcome) included 79 patients who had regression of focal neurological deficit, assessed using the NIHSS, mRS, Rivermead scales. Group II (unfavorable outcome) inclu

APA, Harvard, Vancouver, ISO, and other styles

19

Anand, S., W. Siddhartha, D. R. Karnad, M. Shrivastava, S. Ghatge, and U. S. Limaye. "Heparin or Local Thrombolysis in the Management of Cerebral Venous Sinus Thrombosis?" Interventional Neuroradiology 12, no. 2 (2006): 131–40. http://dx.doi.org/10.1177/159101990601200207.

Full text

Abstract:

Patients with acute cerebral venous sinus thrombosis treated with Heparin or in situ thrombolysis in our department were evaluated in an attempt to rationalize treatment with heparin or thrombolysis. 279 patients with angiographically proven acute cerebral venous sinus thrombosis were included in the study. Patients were classified into mild and severe clinical grade. The study was divided into three phases. Phase I included 27 patients treated with systemic heparin. Phase II included 72 patients, 30 in severe grade and 42 in mild. 26 were thrombolysed with 14 in severe and 12 in mild grade. P

APA, Harvard, Vancouver, ISO, and other styles

20

Virk, Hafeez Ul Hassan, Sanjay Chatterjee, Partha Sardar, Chirag Bavishi, Jay Giri, and Saurav Chatterjee. "Systemic Thrombolysis for Pulmonary Embolism." Interventional Cardiology Clinics 7, no. 1 (2018): 71–80. http://dx.doi.org/10.1016/j.iccl.2017.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Verhaeghe, Raymond. "Thrombolysis in Arterial Occlusion." Thrombosis and Haemostasis 82, S 01 (1999): 109–11. http://dx.doi.org/10.1055/s-0037-1615565.

Full text

Abstract:

SummaryIntra-arterial thrombolytic therapy has replaced systemic intravenous infusion of thrombolytic agents as a treatment modality for arterial occlusion in the limbs. Several catheter-guided techniques and various infusion methods and schemes have been developed. At present there is no scientific proof of definite superiority of any agent in terms of efficacy or safety but clinical practice favours the use of urokinase or alteplase. Studies which compared thrombolysis to surgical intervention suggest that thrombolytic therapy is an appropriate initial management in patients with acute occlu

APA, Harvard, Vancouver, ISO, and other styles

22

Sloot, S., J. Van Nierop, JJ Kootstra, C. Wittens, and WM Fritschy. "Bilateral catheter-directed thrombolysis in a patient with deep venous thrombosis caused by a hypoplastic inferior vena cava." Phlebology: The Journal of Venous Disease 30, no. 4 (2014): 293–95. http://dx.doi.org/10.1177/0268355514524194.

Full text

Abstract:

Introduction Deep venous thrombosis treatment using catheter-directed thrombolysis is advocated over systemic thrombolysis because it reduces bleeding complications. With the development of a catheter that combines ultrasound vibrations and the local delivering of thrombolytics, new and safer treatments appear that are suitable for more complex problems. Report An adolescent male presented with bilateral iliofemoral thrombosis based on a hypoplastic inferior vena cava that had existed for more than two weeks. He was succesfully treated by bilateral ultrasound-accelerated catheter-directed thro

APA, Harvard, Vancouver, ISO, and other styles

23

Bouris, Vasileios, and Efthymios D. Avgerinos. "Catheter-directed interventions in acute pulmonary embolism treatment." Vascular Investigation and Therapy 6, no. 4 (2023): 93–99. http://dx.doi.org/10.4103/vit.vit_11_23.

Full text

Abstract:

Abstract: Catheter-based interventions for acute pulmonary embolism (PE) have evolved over the past decades to achieve the benefits of systemic thrombolysis, avoiding though its systemic complications and offering a therapeutic option to a wider spectrum of PE patients who may be contraindicated for thrombolytics. Although numerous observational, retrospective, or small prospective studies have been performed to evaluate the myriad devices used in the preceding years, few are of adequate quality to support widespread use. However, we were seeing an increasing use of catheter thrombolytic and a

APA, Harvard, Vancouver, ISO, and other styles

24

Antoine, David, Taylor Chuich, Ruben Mylvaganam, et al. "Relationship of left ventricular outflow tract velocity time integral to treatment strategy in submassive and massive pulmonary embolism." Pulmonary Circulation 10, no. 3 (2020): 204589402095372. http://dx.doi.org/10.1177/2045894020953724.

Full text

Abstract:

Pulmonary embolism is associated with high rates of mortality and morbidity. It is important to understand direct comparisons of current interventions to differentiate favorable outcomes and complications. The objective of this study was to compare ultrasound-accelerated thrombolysis versus systemic thrombolysis versus anticoagulation alone and their effect on left ventricular outflow tract velocity time integral. This was a retrospective cohort study of subjects ≥18 years of age with a diagnosis of submassive or massive pulmonary embolism. The primary outcome was the percent change in left ve

APA, Harvard, Vancouver, ISO, and other styles

25

Ho, Vy T., Anahita Dua, Kedar Lavingia, Kara Rothenberg, Christina Rao, and Sapan S. Desai. "Thrombolysis for Venous Thromboembolism During Pregnancy: A Literature Review." Vascular and Endovascular Surgery 52, no. 7 (2018): 527–34. http://dx.doi.org/10.1177/1538574418777822.

Full text

Abstract:

Background: Pregnancy is a hypercoagulable state, conferring an increased risk of venous thromboembolism (VTE). However, treatment algorithms for deep venous thrombosis and pulmonary embolism are based on studies of nonpregnant patients. Methods: A literature review of cases in which thrombolysis was used for the treatment of VTE during pregnancy was conducted using the PubMed (National Institutes of Health) database. Results: A PubMed database search of English language articles for reports of thrombolysis for the treatment of VTE in pregnancy identified 215 cases, including 183 cases of syst

APA, Harvard, Vancouver, ISO, and other styles

26

Chiarello, Matthew, and Akhilesh Sista. "Catheter-Directed Thrombolysis for Submassive Pulmonary Embolism." Seminars in Interventional Radiology 35, no. 02 (2018): 122–28. http://dx.doi.org/10.1055/s-0038-1642041.

Full text

Abstract:

AbstractAcute pulmonary embolism (PE) is a leading cause of morbidity and mortality in the United States. PE associated with right ventricular strain, termed submassive or intermediate-risk PE, is associated with an increased rate of clinical deterioration and short-term mortality. Trials have demonstrated systemic thrombolytics may improve patient outcomes, but they carry a risk of major hemorrhage. Catheter-directed thrombolysis (CDT) may offer similar efficacy to and a lower risk of catastrophic hemorrhage than systemic thrombolysis. Three prospective trials have evaluated CDT for submassiv

APA, Harvard, Vancouver, ISO, and other styles

27

Igor, B. Kovalenko* Zhanna Yu. Chefranova Nadezhda S. Zueva Vyacheslav D. Polyansky. "APPLICATION OF SELECTIVE THROMBOLYTIC THERAPY FOR ISCHEMIC STROKE TREATMENT." Indo American Journal of Pharmaceutical Sciences 04, no. 10 (2017): 3727–31. https://doi.org/10.5281/zenodo.1019479.

Full text

Abstract:

The article deals with the review and analysis of the major study related to both applications of STLT and that compared to systemic thrombolysis which demonstrate good functional results after 90 days of STLT application and less number of intracranial hemorrhage during 24 hours. The comparative analysis of the outcomes of ischemic stroke treatment based on systemic and selective thrombolysis by Actilyse was conducted in Belgorod Regional Clinical Hospital. The procedure of selective thrombolysis was described. The analysis of the effectiveness and complications depending on medication dose a

APA, Harvard, Vancouver, ISO, and other styles

28

Taha, Mohamed AH, Andrew Busuttil, Roshan Bootun, and Alun H. Davies. "A systematic review of paediatric deep venous thrombolysis." Phlebology: The Journal of Venous Disease 34, no. 3 (2018): 179–90. http://dx.doi.org/10.1177/0268355518778660.

Full text

Abstract:

Objectives The aim was to assess the effectiveness and safety of catheter-directed thrombolysis in children with deep venous thrombosis and to evaluate its long-term effect. Method and results EMBASE, Medline and Cochrane databases were searched to identify studies in which paediatric acute deep venous thrombosis patients received thrombolysis. Following title and abstract screening, seven cohort studies with a total of 183 patients were identified. Technical success was 82% and superior in regional rather than systemic thrombolysis (p < 0.00001). One cohort study identified significant dif

APA, Harvard, Vancouver, ISO, and other styles

29

Shokr, Mohamed, Ramanjit Kaur, Kevin Belgrave, et al. "Ultrasound Assisted Catheter Directed Thrombolysis in the Management of a Right Atrial Thrombus: A New Weapon in the Armamentarium?" Case Reports in Cardiology 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/4167397.

Full text

Abstract:

Catheter related thrombosis (CRT) is a commonly encountered entity fraught with substantial risk for mortality secondary to various complications including pulmonary embolism (PE), tricuspid regurgitation, endocarditis, right sided heart failure, and cardiogenic and septic shock. CRT carries a mortality rate of 18% in hemodialysis patients and more than 40% in nonhemodialysis patients. Management strategies include systemic anticoagulation, systemic thrombolysis, surgical evacuation, and percutaneous retrieval with no established guidelines. Ultrasound assisted catheter directed thrombolysis e

APA, Harvard, Vancouver, ISO, and other styles

30

Liu, Guanglin, Yong Wang, and Hongjian Guan. "Successfully intravenous thrombolytic therapy in systemic lupus erythematosus-related ischemic stroke: A case report." Medicine 103, no. 43 (2024): e40203. http://dx.doi.org/10.1097/md.0000000000040203.

Full text

Abstract:

Rationale: Stroke is a relatively frequent complication occurring in patients with systemic lupus erythematosus (SLE). The increasing number of patients with Ischemic Stroke secondary to SLE aroused the clinician’s concern. SLE thrombosis markers, diagnostic high-resolution magnetic resonance image (HR-MRI), and therapeutic interventions for acute ischemic stroke were recently coming into focus perspectives from the field. Patient concerns: A 42-year-old female with slurred speech and numbness in her left limb was admitted to our hospital. Diagnoses: Magnetic resonance imaging (MRI) revealed r

APA, Harvard, Vancouver, ISO, and other styles

31

Molchanova, Zhanna Ivanovna, Lyudmila Ivanovna Anishchenko, Aleksandr Aleksandrovich Rapgof, Elena Viktorovna Shсhedukhina, and Oksana Petrovna Tupilenko. "REPERFUSION THERAPY OF ISCHEMIC STROKE IN THE REGIONAL VASCULAR CENTER OF KHANTY-MANSIYSK." Scientific medical Bulletin of Ugra 34, no. 4 (2022): 39–42. http://dx.doi.org/10.25017/2306-1367-2022-34-4-39-42.

Full text

Abstract:

The case histories of 52 patients with ischemic stroke treated at the regional vascular center of the Khanty-Mansiysk Regional Clinical Hospital for the period from 2019–2021 were analyzed using the method of systemic thrombolytic therapy to analyze the eff ectiveness and further optimize the provision of specialized medical care to stroke patients. In the regional vascular center of the Khanty-Mansiysk Regional Clinical Hospital, systemic thrombolytic therapy is part of routine clinical practice. The number of systemic thrombolysis performed in 2020 and 2021 decreased, which is due to the pec

APA, Harvard, Vancouver, ISO, and other styles

32

Sehweil, S. M. M., and Z. A. Goncharova. "Thrombolytic therapy of cerebral infarction caused by an occlusion in the proximal segment of the middle cerebral artery." Russian neurological journal 29, no. 3 (2024): 41–48. http://dx.doi.org/10.30629/2658-7947-2024-29-3-41-48.

Full text

Abstract:

Introduction. Systemic thrombolysis is a generally recognized highly eff ective treatment for ischemic stroke. Malignant cerebral infarction (MCI) in the territory supplied by the middle cerebral artery is characterized by a lesion affecting 50 % or more of the vascular territory therefore acting as a contraindication to systemic thrombolytic therapy. At the same time, when admitted to the hospital during the therapeutic time window, some patients with MCI remain candidates for systemic thrombolysis until an infarcted focus is identifi ed in the area supplied by the middle cerebral artery (MCA

APA, Harvard, Vancouver, ISO, and other styles

33

Jain, Sachin Kumar Amruthlal, Brijesh Patel, Wadie David, Ayad Jazrawi, and Patrick Alexander. "Unloading of Right Ventricle and Clinical Improvement after Ultrasound-Accelerated Thrombolysis in Patients with Submassive Pulmonary Embolism." Case Reports in Medicine 2014 (2014): 1–8. http://dx.doi.org/10.1155/2014/297951.

Full text

Abstract:

Acute pulmonary embolism (PE) can be devastating. It is classified into three categories based on clinical scenario, elevated biomarkers, radiographic or echocardiographic features of right ventricular strain, and hemodynamic instability. Submassive PE is diagnosed when a patient has elevated biomarkers, CT-scan, or echocardiogram showing right ventricular strain and no signs of hemodynamic compromise. Thromboemboli in the acute setting increase pulmonary vascular resistance by obstruction and vasoconstriction, resulting in pulmonary hypertension. This, further, deteriorates symptoms and hemod

APA, Harvard, Vancouver, ISO, and other styles

34

Maksimova, M. Yu, A. G. Brutyan, and E. V. Shalimanova. "Systemic Thrombolysis and Post-stroke Epilepsy." Human Physiology 46, no. 8 (2020): 823–32. http://dx.doi.org/10.1134/s0362119720080095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Steensrud, T., L. S. Ording Muller, and D. Sorlie. "Unilateral adrenal haemorrhage following systemic thrombolysis." Interactive CardioVascular and Thoracic Surgery 7, no. 3 (2008): 430–31. http://dx.doi.org/10.1510/icvts.2007.170795.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Tassi, Rossana, Maurizio Acampa, Giovanna Marotta, et al. "Systemic thrombolysis for stroke in pregnancy." American Journal of Emergency Medicine 31, no. 2 (2013): 448.e1–448.e3. http://dx.doi.org/10.1016/j.ajem.2012.05.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bartel, Billie. "Systemic thrombolysis for acute pulmonary embolism." Hospital Practice 43, no. 1 (2015): 22–27. http://dx.doi.org/10.1080/21548331.2015.1001302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

KOHLI, AKSHAY, MICHAEL OBREGON, ROBERT KROPP, ABHISHEK KALIDAS KULKARNI, and PRASHANT JAGTAP. "MECHANICAL THROMBECTOMY AFTER FAILED SYSTEMIC THROMBOLYSIS." CHEST 164, no. 4 (2023): A2051—A2052. http://dx.doi.org/10.1016/j.chest.2023.07.1403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sposato, Luciano A., Valeria Salutto, Diego E. Beratti, Paula Monti, Patricia M. Riccio, and Claudio Mazia. "Adverse Outcome of Early Recurrent Ischemic Stroke Secondary to Atrial Fibrillation after Repeated Systemic Thrombolysis." Case Reports in Vascular Medicine 2013 (2013): 1–4. http://dx.doi.org/10.1155/2013/371642.

Full text

Abstract:

Background. Recurrent ischemic stroke is associated with adverse neurological outcome in patients with atrial fibrillation. There is very scarce information regarding the neurological outcome of atrial fibrillation patients undergoing repeated systemic thrombolysis after early recurrent ischemic stroke.Clinical Case and Discussion. We describe a case of a 76-year-old woman with known paroxysmal atrial fibrillation who was admitted because of an acute right middle cerebral artery ischemic stroke and who underwent repeated systemic thrombolysis within 110 hours. The patient underwent systemic th

APA, Harvard, Vancouver, ISO, and other styles

40

Patel, Nileshkumar, Amina Saqib, Jasvinder Singh, et al. "Systemic Thrombolysis Compared to Catheter Directed Thrombolysis in Acute Pulmonary Embolism." Chest 148, no. 4 (2015): 919A. http://dx.doi.org/10.1378/chest.2265015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bottinor, Wendy, Jeremy Turlington, Syed Raza, et al. "Life-Saving Systemic Thrombolysis in a Patient with Massive Pulmonary Embolism and a Recent Hemorrhagic Cerebrovascular Accident." Texas Heart Institute Journal 41, no. 2 (2014): 174–76. http://dx.doi.org/10.14503/thij-12-3010.

Full text

Abstract:

Massive pulmonary embolism is associated with mortality rates exceeding 50%. Current practice guidelines include the immediate administration of thrombolytic therapy in the absence of contraindications. However, thrombolysis for pulmonary embolism is said to be absolutely contraindicated in the presence of recent hemorrhagic stroke and other conditions. The current contraindications to thrombolytic therapy have been extrapolated from data on acute coronary syndrome and are not specific for venous thromboembolic disease. Some investigators have proposed that the current contraindications be vie

APA, Harvard, Vancouver, ISO, and other styles

42

Feng, Jeremy Y., Charles B. Ross, and Rachel P. Rosovsky. "Urban-Rural Variation in Use of Thrombolytic Therapy for Pulmonary Embolism." Blood 134, Supplement_1 (2019): 3409. http://dx.doi.org/10.1182/blood-2019-125493.

Full text

Abstract:

Background: Thrombolytic therapy is widely accepted for persistent hypotension or shock due to acute pulmonary embolism (PE), with randomized and observational studies demonstrating earlier hemodynamic improvement and possible mortality benefit. The extent to which thrombolytic therapy is used in urban versus non-urban settings is unclear. Methods: We conducted a retrospective cohort study of 92,706 (unweighted) and 180,189 (weighted) admissions with primary diagnosis of PE, for patient aged 18 years and above, that occurred in 2016, at all general acute-care hospitals within the 27 states inc

APA, Harvard, Vancouver, ISO, and other styles

43

Goldenberg, Neil A., Janette D. Durham, R. Knapp-Clevenger, and Marilyn J. Manco-Johnson. "A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children." Blood 110, no. 1 (2007): 45–53. http://dx.doi.org/10.1182/blood-2006-12-061234.

Full text

Abstract:

Important predictors of adverse outcomes of thrombosis in children, including postthrombotic syndrome (PTS), have recently been identified. Given this knowledge and the encouraging preliminary pediatric experience with systemic thrombolysis, we sought to retrospectively analyze our institutional experience with a thrombolytic regimen versus standard anticoagulation for acute, occlusive deep venous thrombosis (DVT) of the proximal lower extremities in children in whom plasma factor VIII activity and/or D-dimer concentration were elevated at diagnosis, from within a longitudinal pediatric cohort

APA, Harvard, Vancouver, ISO, and other styles

44

Stringer, Kathleen A. "Beyond Thrombolysis: Other Effects of Thrombolytic Drugs." Annals of Pharmacotherapy 28, no. 6 (1994): 752–56. http://dx.doi.org/10.1177/106002809402800613.

Full text

Abstract:

OBJECTIVE: To review the effects of plasminogen activators (tissue plasminogen activator, streptokinase, and anistreplase) on fibrinogen and thrombin, platelets, complement, blood rheology, and neutrophils. DATA SOURCES: A MEDLINE search, as well as a review of recent scientific abstracts, was conducted to identify pertinent literature. STUDY SELECTION: Focus was placed on studies conducted in humans. However, many in vitro studies have been performed to fully elucidate the effect of plasminogen activators on different aspects of hemostasis and on the fibrinolytic and immune systems. DATA EXTR

APA, Harvard, Vancouver, ISO, and other styles

45

Islam, Marjan, David Nesheim, Samuel Acquah, et al. "Right Heart Thrombi: Patient Outcomes by Treatment Modality and Predictors of Mortality: A Pooled Analysis." Journal of Intensive Care Medicine 34, no. 11-12 (2018): 930–37. http://dx.doi.org/10.1177/0885066618808193.

Full text

Abstract:

Rationale: Right heart thrombi (RiHT) is characterized by the presence of thrombus within the right atrium or right ventricle (RV). Current literature suggests pulmonary embolism (PE) with RiHT carries a high mortality. Guidelines lack recommendations in managing RiHT. We created a pooled analysis on RiHT and report on our institutional experience in managing RiHT. We aimed to evaluate whether patient characteristics and differing treatment modalities predict mortality. Methods: We created a pooled analysis of case reports and series of patients with RiHT and PE between January 1956 and 2017.

APA, Harvard, Vancouver, ISO, and other styles

46

Griffith, Kevin E., Eric Jenkins, and Jonathan Haft. "Treatment of massive pulmonary embolism utilizing a multidisciplinary approach: a case study." Perfusion 24, no. 3 (2009): 169–72. http://dx.doi.org/10.1177/0267659109346663.

Full text

Abstract:

Massive pulmonary embolism (PE) is associated, historically, with a high mortality rate.Treatment options include systemic anticoagulation, catheter-directed thrombolytic therapy, surgical embolectomy, fragmentation techniques, and catheter embolectomy. Extracorporeal membrane oxygenation (ECMO) repeatedly has demonstrated effectiveness in providing cardiopulmonary support for the patient with a massive PE too unstable to undergo thrombolysis or embolectomy. The present case study describes a morbidly obese patient, status post gastric bypass surgery, who presented with PE, and acute respirato

APA, Harvard, Vancouver, ISO, and other styles

47

Averkov, O. V., and V. I. Vechorko. "Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?" Russian Journal of Cardiology, no. 9 (September 24, 2018): 65–70. http://dx.doi.org/10.15829/1560-4071-2018-9-65-70.

Full text

Abstract:

Primary percutaneous intervention (PCI) is a preferable reperfusion method in patients with STEMI. If on-time PCI is not possible, pharmacoinvasive approach is recommended that includes urgent systemic thrombolysis. Regardless the broad usage of ticagrelor in MI patients, its safety in combination with thrombolysis (first 24 hours from STEMI onset) before the year 2018 was unknown. In the TREAT study the patients 18-75 year old with STEMI (symptom onset within 24 hours), received thrombolytic drug, were randomized to ticagrelor or clopidogrel group. In 30 days from randomization it was shown t

APA, Harvard, Vancouver, ISO, and other styles

48

Nikolskiy, A. V., V. N. Kravchuk, A. S. Mukhin, et al. "Results of treatment of acute arterial thrombosis in patients with severe course of coronavirus infection COVID-19." Hirurg (Surgeon), no. 5 (October 22, 2022): 17–27. http://dx.doi.org/10.33920/med-15-2205-03.

Full text

Abstract:

Acute arterial thrombosis against the background of the novel coronavirus infection COVID-19 is an unfavorable complication. The survival prognosis in this category of patients is much worse than in the rest of the patient population. The aim of the work is to compare the immediate results of various methods of treating acute arterial insufficiency in patients with the novel coronavirus infection COVID-19, complicated by the development of acute arterial thrombosis of various localizations. 42 clinical cases of treatment of acute arterial pathology in patients with confirmed COVID-19 infection

APA, Harvard, Vancouver, ISO, and other styles

49

Kafke, Waldemar, Peter Kraft, and Department of Neurology. "Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report." Case Reports in Neurology 8, no. 2 (2016): 140–44. http://dx.doi.org/10.1159/000447531.

Full text

Abstract:

We describe a 75-year-old female patient with nonvalvular atrial fibrillation who presented with acute ischemic stroke during treatment with dabigatran 2 × 110 mg per day. After informed consent, we reversed the anticoagulant effects of dabigatran using idarucizumab and applied an intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (off-label use). An intracerebral hemorrhage was excluded after systemic thrombolysis. Despite the IVT, the patient’s clinical condition deteriorated and she developed an ischemic lesion in the right pons, the right thalamus and right cerebe

APA, Harvard, Vancouver, ISO, and other styles

50

Taniguchi, Masatoshi, Yumiko Moritani, Kazumi Hayashi, et al. "Antithrombotic and thrombolytic efficacy of YM-254890, a Gq/11 inhibitor, in a rat model of arterial thrombosis." Thrombosis and Haemostasis 90, no. 09 (2003): 406–13. http://dx.doi.org/10.1160/th03-02-0115.

Full text

Abstract:

SummaryWe examined the antithrombotic and thrombolytic effects of the Gq/11 inhibitor YM-254890 in an electrically-induced carotid artery thrombosis model in rats. YM-254890 dose-dependently inhibited ex vivo ADP-induced platelet aggregation after i.v. bolus injection. In the thrombosis study, YM-254890 dose-dependently prolonged time to occlusion at doses of 3 and 10 μg/kg i.v. and decreased occlusion rate at 10 μg/kg i.v. In the thrombolysis study, YM-254890 at 30 μg/kg i.v. shortened the time to reperfusion and prevented reocclusion after thrombolysis with a modified tissue-type plasminogen

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!